|
gptkbp:instanceOf
|
gptkb:antibiotic
glycopeptide antibiotic
|
|
gptkbp:activeIn
|
gptkb:methicillin-resistant_Staphylococcus_aureus
vancomycin-resistant Enterococcus faecalis
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J01XA04
|
|
gptkbp:brand
|
gptkb:Orbactiv
|
|
gptkbp:CASNumber
|
171099-57-3
|
|
gptkbp:chemicalFormula
|
C86H97Cl3N10O19
|
|
gptkbp:contraindication
|
hypersensitivity to oritavancin
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:eliminationHalfLife
|
245 hours
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oritavancin
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:The_Medicines_Company
|
|
gptkbp:mechanismOfAction
|
inhibits cell wall synthesis
disrupts bacterial membrane
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
1793.2 g/mol
|
|
gptkbp:proteinBinding
|
85%
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
headache
infusion-related reactions
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
|
|
gptkbp:usedFor
|
treatment of acute bacterial skin and skin structure infections
|
|
gptkbp:bfsParent
|
gptkb:Glycopeptides
|
|
gptkbp:bfsLayer
|
5
|